```html

Xanthomas Tendinosus: A Comprehensive Patient Guide

Overview

Xanthomas tendinosus, also called tendon xanthoma, are firm, yellow‑orange nodules that develop within large tendons—most commonly the Achilles tendon, extensor tendons of the hands, and the patellar tendon. The lesions are composed of lipid‑laden macrophages (foam cells) that accumulate in the connective tissue.

These growths are most frequently a cutaneous sign of an underlying lipid metabolism disorder, especially familial hypercholesterolemia (FH). While the nodules themselves are benign, their presence strongly indicates a high lifelong risk of premature atherosclerotic cardiovascular disease.

Who is affected?

• Men are slightly more likely than women to develop tendon xanthomas, reflecting the higher prevalence of FH in males.
• The condition commonly appears in the second or third decade of life, but it can be identified in children with homozygous FH.
• Populations with a higher prevalence of FH—such as those of South‑Asian, Middle‑Eastern, or Ashkenazi Jewish descent—show a correspondingly higher rate of tendon xanthomas.

Prevalence – Heterozygous FH occurs in roughly 1 in 250 individuals worldwide (≈0.4 %), and up to 30 % of those patients develop tendon xanthomas at some point in their life [1,2]. Because many cases go undiagnosed, the true prevalence of tendon xanthomas is likely higher.

Symptoms

Tendon xanthomas are usually painless, but they can cause discomfort or functional limitation depending on size and location. Common symptoms include:

Visible and palpable signs

• Yellow‑orange nodules that feel firm or rubbery.
• Enlarged tendons, especially the Achilles or extensor tendons of the fingers.
• Symmetrical distribution – lesions often appear on both sides of the body.

Functional complaints

• Reduced range of motion in the affected joint (e.g., difficulty flexing the ankle with a large Achilles xanthoma).
• Localized pain or tenderness when the nodule is compressed or after prolonged activity.
• Skin changes – occasional overlying erythema if the lesion becomes inflamed.

Systemic clues

• History of early‑onset coronary artery disease or peripheral arterial disease.
• Family history of high cholesterol, heart attacks, or known FH.

Causes and Risk Factors

Tendon xanthomas are not a disease themselves; they are a manifestation of abnormal lipid metabolism.

Primary cause

• Familial hypercholesterolemia (FH) – Mutations in the LDL‑R, APOB, or PCSK9 genes impair low‑density lipoprotein (LDL) clearance, leading to chronically elevated LDL‑cholesterol (LDL‑C) levels. The excess LDL infiltrates the intima of tendons where macrophages ingest the lipids and become foam cells.

Secondary contributors

• Secondary hyperlipidemia due to uncontrolled diabetes, hypothyroidism, nephrotic syndrome, or certain medications (e.g., glucocorticoids, antiretroviral therapy).
• Rare lipid storage disorders such as sitosterolemia or cerebrotendinous xanthomatosis.

Risk factors for developing tendon xanthomas

• Genetically confirmed FH (heterozygous or homozygous).
• LDL‑C levels > 190 mg/dL (≈5 mmol/L) in adults or > 160 mg/dL (≈4 mmol/L) in children with FH.
• Male sex (moderate increase).
• Family members with known tendon xanthomas.
• Long‑standing untreated hyperlipidemia (duration > 10 years).

Diagnosis

Diagnosis combines a visual/physical exam with laboratory and imaging studies.

Clinical examination

• Inspection for yellow‑orange nodules on tendons.
• Palpation to assess firmness, size, and symmetry.
• Measurement of Achilles tendon thickness (normal < 6 mm in females, < 7 mm in males).

Laboratory testing

• Lipid panel – fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing for FH‑related mutations (recommended when LDL‑C > 190 mg/dL or there is a strong family history).
• Secondary work‑up if FH is excluded: thyroid‑stimulating hormone (TSH), fasting glucose/HbA1c, renal function, urine protein.

Imaging

• Ultrasound – non‑invasive, measures tendon thickness and visualizes hyperechoic nodules.
• Magnetic Resonance Imaging (MRI) – provides detailed tissue characterization; useful for surgical planning.
• CT scan – occasionally used to assess calcification within large xanthomas.

Biopsy (rare)

Fine‑needle aspiration or excisional biopsy confirms lipid‑laden macrophages but is usually unnecessary once clinical and imaging findings align.

Treatment Options

Therapy targets two goals: reduce the underlying lipid burden and manage the physical lesion.

1. Lipid‑lowering medications

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line; reduce LDL‑C by 30‑50 %.
• Ezetimibe – added when statin alone is insufficient (< 100 mg/dL LDL‑C target).
• PCSK9 inhibitors (alirocumab, evolocumab) – powerful LDL‑C reducers (≈60 % additional drop); especially useful in FH.
• Bile‑acid sequestrants and fibric acid derivatives – adjuncts for mixed dyslipidemia.

In homozygous FH, LDL‑apheresis (plasma filtration) may be required to achieve target LDL‑C levels.

2. Lifestyle modifications

• Diet – plant‑sterol–enriched foods, soluble fiber, limited saturated and trans fats.
• Physical activity – at least 150 min/week of moderate aerobic exercise; improves HDL‑C and overall cardiovascular risk.
• Weight management – maintaining BMI < 25 kg/m² reduces secondary hyperlipidemia.
• Smoking cessation – eliminates an independent cardiovascular risk factor.

3. Direct treatment of the xanthoma

• Surgical excision – considered for large, painful, or function‑limiting lesions; recurrence is rare if lipid levels are controlled.
• Laser therapy (CO₂ or Nd:YAG) – useful for superficial lesions, especially on the hands.
• Intralesional corticosteroid injection – provides temporary reduction in size but does not treat the underlying lipid cause.

4. Emerging therapies

• Inclisiran – a small‑interfering RNA that reduces PCSK9 synthesis; administered twice yearly.
• Gene‑editing approaches (CRISPR) – currently in clinical trials for FH, with the potential to correct LDL‑R mutations.

Living with Xanthomas Tendinosus

While the lesions themselves are benign, they can affect quality of life. Below are practical tips for daily management:

• Regular lipid monitoring – check fasting lipid panel every 3–6 months while on therapy.
• Footwear choices – wear well‑fitted, cushioned shoes to minimize pressure on Achilles xanthomas.
• Skin care – keep the overlying skin clean and moisturized; avoid trauma that could cause inflammation or ulceration.
• Exercise adaptation – if a tendon xanthoma limits motion, work with a physical therapist to modify activities (e.g., swimming instead of running).
• Family screening – first‑degree relatives should have lipid panels and, if indicated, genetic testing.
• Medication adherence – set reminders, use pill organizers, and discuss any side effects with your clinician.
• Psychological support – visible lesions can cause self‑consciousness; counseling or support groups for FH patients are beneficial.

Prevention

Because tendon xanthomas arise from prolonged high LDL‑C, prevention focuses on early detection and control of lipid disorders.

• Universal lipid screening – recommended at ages 9–11 and again at 17–21 (American Academy of Pediatrics). Earlier testing for children with a family history of FH.
• Proactive treatment of FH – initiate statins in children ≥ 8 years with confirmed heterozygous FH, per NHLBI guidelines.
• Healthy lifestyle from youth – balanced diet, regular activity, and avoidance of tobacco.
• Genetic counseling – for families with known FH mutations, to inform reproductive decisions and cascade testing.

Complications

If left untreated, tendon xanthomas themselves are usually harmless, but they signal severe hyperlipidemia that can lead to serious complications:

• Atherosclerotic cardiovascular disease – premature coronary artery disease, myocardial infarction, stroke.
• Peripheral arterial disease – claudication, ulceration, possible limb loss.
• Valve disease – aortic valve calcification is more common in FH.
• Secondary inflammation – large xanthomas may become irritated or infected, causing pain and swelling.
• Psychosocial impact – body‑image concerns, anxiety, or depression.

When to Seek Emergency Care

---

References

1. Nordestgaard BG, et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population.” European Heart Journal. 2020;41:2458‑2475.
2. Goldberg AC, et al. “Tendon xanthomas in heterozygous familial hypercholesterolemia.” J Clin Lipidol. 2021;15(3):386‑392.
3. Mayo Clinic. “Familial hypercholesterolemma (genetic high cholesterol).” Accessed June 2024.
4. National Lipid Association. “Guidelines for the Management of Familial Hypercholesterolemia.” 2022.
5. U.S. CDC. “Stroke Signs & Symptoms.” Updated 2023.
6. American Heart Association. “Heart Attack Warning Signs.” 2023.

```